Research company Hamlet Biopharma’s subsidiary Alpha1H BC and partner Linnane Pharma have entered into a non-binding letter of intent with an undisclosed company in uro-oncology in northern Germany regarding the continued development and global commercialization of the drug candidate Alpha 1H for the treatment of bladder cancer. This is stated in a press release.The agreement outlines the terms for a future commercial collaboration but is conditional upon completion of due diligence by all parties, as well as further negotiations before a final agreement can be signed."The dialogue with our potential partner has been very constructive and forward-looking. At this stage, the focus is on completing the clinical development in the best possible way, scaling up manufacturing, and establishing the right commercial frameworks to plan market access," comments Catharina Svanborg, chair of Hamlet Biopharma.